NewsBenzinga모건스탠리, 아토비아 테라퓨틱스 비중확대 의견 유지···목표주가 40달러로 상향 모건스탠리, 아토비아 테라퓨틱스 비중확대 의견 유지···목표주가 40달러로 상향 Benzinga 2026.11.10 17:00 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 Ex-Carlyle Executive Launches Asia Secondaries Firm as $3 Trillion Sits Locked in Private Funds 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report